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SUMMARY
A large-scale RNA interference screen to discover genes involved in trastuzumab resistance in breast
cancer identified only PTEN as a modulator of drug sensitivity. Oncogenic mutants of PIK3CA
(activator of the same pathway and frequently mutated in breast cancer) also conferred resistance
to trastuzumab in cell culture. In a cohort of 55 breast cancer patients, activation of the PI3K pathway,
as judged by the presence of oncogenic PIK3CAmutations or low PTEN expression, was associated
with poor prognosis after trastuzumab therapy, and the combined analysis of PTEN and PIK3CA
identified twice as many patients at increased risk for progression compared to PTEN alone. Thus,
assessment of PI3K pathway activation may provide a biomarker to identify patients unlikely to
respond to trastuzumab-based therapy.INTRODUCTION
Themechanismbywhich trastuzumab exerts its antitumor
activity is not fully understood. Trastuzumab has been
suggested to induce antibody-dependent cellular cyto-
toxicity (ADCC) (Clynes et al., 2000), inhibit HER2 extracel-
lular domain cleavage (Molina et al., 2001), or inhibit PI3K/
AKT survival signaling, either by downregulating HER2
signaling (Yakes et al., 2002) or by increasing PTEN mem-
brane localization and phosphatase activity, leading to
a decline in PI3K/AKT pathway activation and inhibition
of proliferation (Nagata et al., 2004). In addition, activation
of HER-related receptors, such as HER3, or non-HERCreceptors, such as insulin-like growth factor I receptor,
have been suggested in preclinical studies to increase
PI3K/AKT signaling thereby limiting trastuzumab efficacy
(Lu et al., 2001; Sergina et al., 2007). In spite of this, it is still
largely unclear why almost half of the breast cancer
patients that overexpress HER2 are initially nonresponsive
to trastuzumab-based therapy even when combined with
chemotherapy or eventually become resistant to trastuzu-
mab during treatment (Cobleigh et al., 1999; Slamon et al.,
2001; Vogel et al., 2002). An understanding of the resis-
tance mechanisms would stimulate the development of
rational drug combinations to circumvent resistance and
allow better selection of patients likely to respond.SIGNIFICANCE
Availability of biomarkers that predict responses to cancer therapy is instrumental to the rational use of cancer
drugs in the clinic. Elucidating the molecular mechanism of primary or acquired drug resistance can be critical
to identify patients that fail to respond to therapy and may help design more efficient treatment protocols. We pres-
ent here a method to identify biomarkers associated with nonresponsiveness to cancer drugs in cell culture and
demonstrate that these biomarkers have predictive value in a patient cohort treated with this drug, thus validating
the approach.ancer Cell 12, 395–402, October 2007 ª2007 Elsevier Inc. 395
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As an unbiased approach to identify genes involved in
trastuzumab resistance, we used a large-scale RNA inter-
ference genetic screen in the HER2-overexpressing
breast cancer cell line BT-474. We have previously
described the generation of a library of 24,000 shRNA
retroviral vectors targeting some 8000 human genes for
suppression by RNA interference as well as a technology
to rapidly screen such libraries, named siRNA barcode
screening (Berns et al., 2004; Brummelkamp et al.,
2006). In short, this technology allows one to identify
shRNAs that are enriched in a population based on the
relative abundance of a ‘‘barcode’’ identifier (a unique
19-mer DNA sequence) in the vector, which is measured
on a DNA microarray that carries the 24,000 different
barcode sequences. BT-474 cells respond to trastuzu-
mab predominantly by a reduction in proliferation rate
rather than apoptosis or complete proliferation arrest
(Figure 1A). To identify genes whose suppression by
shRNA cause resistance to trastuzumab, BT-474 cells
were infected with the shRNA library and selected for
the presence of the shRNA vectors with puromycin. After
selection, cells were split into two populations and plated
at low density. One population was left untreated and
was used as a reference while the other was exposed to
10 mg/ml trastuzumab. After 4 weeks, cells were har-
vested, genomic DNA isolated, and shRNA cassettes
were recovered by PCR amplification and hybridized to
DNA microarrays as described (Berns et al., 2004)
(Figure 1B). We combined the data from five independent
trastuzumab barcode screens and analyzed the relative
abundance of the recovered shRNAs. Figure 1C shows
the relative abundance of the shRNA vectors in the trastu-
zumab-treated population as compared to the untreated
population. We selected the top 5 shRNA vectors with
the highest enrichment by trastuzumab selection (IDE,
NBS1, PTEN, NRP1, and ZAP70), of which the shRNA tar-
geting the PTEN tumor suppressor gene was most prom-
inently enriched (marked with an arrow). When tested in
second round selection, only the vector targeting PTEN
conferred resistance to trastuzumab. Importantly, a sec-
ond, independent shRNA knocking down PTEN expres-
sion (Kortlever et al., 2006) also conferred resistance to
trastuzumab, effectively ruling out the possibility that
‘‘off target’’ effects of the shRNA vectors caused the resis-
tance phenotype (Figure 2A).
Our finding that knockdown of PTEN in BT-474 cells
decreases sensitivity to trastuzumab is consistent with
earlier findings which demonstrated that PTEN loss is
associated with resistance to trastuzumab-based therapy
(Nagata et al., 2004). Importantly, our observation that of
the 8000 genes tested, only knockdown of PTEN con-
ferred resistance to trastuzumab suggests that the PTEN
pathway plays a dominant role in trastuzumab resistance.
However, we cannot eliminate the possibility that other
factors were missed in our screen due to false negative
results of the shRNA vectors. Since loss of PTEN is only
observed in a fraction of breast cancers, it is unlikely396 Cancer Cell 12, 395–402, October 2007 ª2007 Elsevier Inc.that loss of PTEN alone explains the frequent primary
and acquired nonresponsiveness to trastuzumab ob-
served in the clinic. Loss-of-function mutations in PTEN
or decreased PTEN expression result in hyperactivation
of the PI3K pathway. Significantly, activating mutations
in the gene encoding the p110a catalytic subunit of PI3K
(PIK3CA) have been identified in some 25% of primary
breast cancers potentially mimicking the effects of PTEN
loss (Saal et al., 2005). The majority of these mutations
reside in two hotspots in exon 9 and 20 and it has been
demonstrated that the two most common mutations
(E545K andH1047R) result in increased PI3K pathway sig-
naling (Isakoff et al., 2005).
To test whether activation of the PI3K pathway up-
stream of PTEN results in trastuzumab resistance, we ret-
rovirally transduced BT-474 cells with a constitutively ac-
tive mutant of PIK3CA, caPIK3CA (p110aCaaX). Figure 2A
shows that expression of this mutant rendered BT-474
almost completely insensitive toward trastuzumab. Fur-
thermore, expression of PIK3CA(WT) and the breast can-
cer-derived mutant PIK3CA(H1047R) also conferred re-
sistance to trastuzumab in SK-BR3 cells (Figure 2B) and
in BT-474 cells (data not shown). As expected, the onco-
genic mutant displays higher PI3K activity than wild-type
PIK3CA as measured by AKT S473 phosphorylation sta-
tus (Figure 2C). However, a small increase in PI3K signal-
ing through overexpression of PIK3CA(WT) is already suf-
ficient to completely counteract the growth inhibitory
effects of trastuzumab in cell culture as was further shown
by analysis of the proliferation rates of BT474 cell lines
expressing PIK3CA(WT) (Figure 2D). These findings are
consistent with a major role of the PI3K pathway in the de-
velopment of resistance to trastuzumab.
The high frequency of activating mutations in PIK3CA
(around 25%; Saal et al., 2005) in breast cancer, together
with our observation that activated PI3K signaling induces
strong trastuzumab resistance in cell culture, led us to in-
vestigate whether PI3K pathway activity, as assessed by
cancer-associated mutations of PIK3CA or altered levels
of PTEN, was able to predict trastuzumab resistance in
theclinic. For this,wemadeuseof samples from twoseries
of HER2-overexpressing patients with metastatic breast
cancer treated at the Antoni van Leeuwenhoek Hospital
(n = 34) and the M.D. Anderson Cancer Center (n = 21).
These 55 patients received trastuzumab monotherapy
(n=6), or trastuzumab incombinationwithachemotherapy
regimen (n = 49). Both the PTEN expression levels (using
immunohistochemical analysis) and the PIK3CAmutation
status (by direct sequencing or SNP-based analysis)
were evaluated in this study and correlated to the thera-
peutic response to trastuzumab-based therapy (see
Experimental Procedures and Figures S1 and S2 in the
Supplemental Data available with this article online).
We observed reduced PTEN expression in 22% (11 out
of 51; four samples could not be scored) of the tumors ex-
amined (Table S1). Kaplan-Meier survival curves were
generated based on clinical follow-up data on time to pro-
gression after initiation of the trastuzumab-based treat-
ment. Figure 3A shows that patients with PTEN low tumors
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Resistance to Trastuzumab in Breast CancerFigure 1. shRNA Barcode Screen Identifies PTEN as a Modulator of Trastuzumab Efficacy
(A) BT-474 cells undergo a stable proliferation arrest upon trastuzumab treatment. One hundred thousand BT-474 cells were seeded and cultured for
10 d in absence or presence of 2 mg/ml trastuzumab, after which cells were photographed, fixed, and stained.
(B) Schematic outline of the trastuzumab resistance barcode screen performed in BT-474 cells. High titer shRNA library polyclonal virus was
produced and used to infect BT-474 cells. Infected cells were left untreated (control) or were treated with 10 mg/ml trastuzumab. After 4 weeks of
selection, shRNA cassettes were recovered from both control and treated populations and labeled as described (Berns et al., 2004).
(C) Analysis of the relative abundance of the recovered shRNA cassettes from trastuzumab barcode experiment. Data were normalized and 2log
transformed. Depicted is the average of five independent experiments. All hybridizations were performed with reverse color swap.have a somewhat worse progression-free survival, al-
though this is not statistically significant (p = 0.127). Sub-
sequent PIK3CA sequence analysis of the 55 tumor sam-
ples identified 10 mutations in exon 20 (H1047R) and 4 in
exon 9 (E542K and E545K) corresponding to a PIK3CA
mutation frequency of 25%, in agreement with the pub-
lished frequency of PIK3CA mutations in breast cancer
(Saal et al., 2005; Table S1). Interestingly, 10 of 14 of the
PIK3CA mutations were identified in PTEN high tumorsC(for three PIK3CA mutations PTEN data were missing),
which is in agreement with the finding that PTEN loss
and PIK3CAmutation are rarely present in the same tumor
in breast cancer (Saal et al., 2005). Apparently, abrogation
of either PTEN expression or oncogenic PIK3CAmutation
relieves the selective pressure to target the other. We then
determined whether activation of the PI3K pathway by on-
cogenic PIK3CA mutation would predict trastuzumab-
based treatment outcome. The Kaplan-Meier survivalancer Cell 12, 395–402, October 2007 ª2007 Elsevier Inc. 397
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Resistance to Trastuzumab in Breast CancerFigure 2. PTEN Downregulation and Active PI3K Signaling Confer Trastuzumab Resistance in Cell Culture
(A) Knockdown of PTEN confers resistance to trastuzumab arrest in BT-474 cells. The NKi library vector targeting PTEN (L), a second independent
shRNA vector targeting PTEN, and a constitutive active PIK3CA mutant were introduced into BT-474 cells. Infected cells were left untreated () or
incubated with trastuzumab (10 mg/ml). After 3 weeks cells were photographed, fixed, and stained.
(B) SK-BR3 cells were infected with PIK3CA(WT) and PIK3CA(H1047R) retroviral vectors and cultured in the absence () or presence of 10 mg/ml
trastuzumab for 3 weeks, after which cells were photographed, fixed, and stained.
(C) Phospho AKT western analysis of SK-BR3 cell lines stably infected with indicated retroviral vectors. Lysates were generated from cells cultured in
the absence () or presence (+) of 10 mg/ml trastuzumab overnight.
(D) Growth curves of stably infected BT474 cells that were cultured for 4 weeks in the absence and presence of 2 mg/ml trastuzumab. Cell numbers
were quantified as described in the Experimental Procedures. Growth curves were performed multiple times in triplicate with error bars depicting the
mean ± SD.398 Cancer Cell 12, 395–402, October 2007 ª2007 Elsevier Inc.
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Resistance to Trastuzumab in Breast CancerFigure 3. Kaplan-Meier Survival Curves for Trastuzumab-
Treated HER2-Positive Patients
(A) Patients from both cohorts were divided into PTEN low (IRS 0–3)
and PTEN high (IRS 4–12) based on IHC and semiquantitation of
PTEN levels using immunoreactive scores (IRS; see the Experimental
Procedures). Time to progression was calculated from start date of
trastuzumab-based treatment until time of first progression of disease.Cacurve in Figure 3B indeed demonstrates shorter progres-
sion-free survival among patients with mutation-positive
tumors, which has a borderline statistical significance
(p = 0.052). However, the PIK3CA wild-type tumors are
contaminated with 25% (10 out of 40) PTEN low tumors,
which appear associated with shorter time to disease
progression (Figure 3A). Since PTEN loss and PIK3CA
mutation both contribute to PI3K pathway activation, we
classified the patients in two groups having either ‘‘acti-
vated’’ PI3K pathway (PTEN low or PIK3CA mutants;
n = 24) and ‘‘not-activated’’ PI3K pathway (PTEN high +
PIK3CA WT; n = 29) and generated Kaplan-Meier survival
plots. The curves shown in Figure 3C demonstrate that
patients with an activated PI3K pathway due to either
PTEN loss or PIK3CAmutation have a significantly shorter
progression-free survival following trastuzumab-based
treatment than patients without PTEN loss or PIK3CA
mutation. Importantly, the progression-free survival differ-
ence between the two groups only reached statistical
significance (p = 0.007) when both events (PTEN loss or
PIK3CA mutation) were considered together. Hazard
ratios based on multivariate Cox regression analysis with
age as time scale, stratified for center and adjusted for
ER status, indicate that PI3K pathway status is an inde-
pendent significant risk factor for disease progression
(HR = 1.9, p = 0.048; Table 1). Hazard ratios for the sepa-
rate risk factors PTEN loss or PIK3CA mutation were not
significant (Table 1). These data suggest that combined
PTEN expression and PIK3CA hotspot mutation analysis
may serve as an important predictor for risk for progres-
sion after trastuzumab-based therapy. There was no evi-
dence of heterogeneity of the effects of PTEN and PIK3CA
between the two centers.
DISCUSSION
We identified the tumor suppressor PTEN in an unbiased
genome-wide RNAi screen for genes that modulate resis-
tance to trastuzumab and demonstrate the importance of
PI3K pathway activation as a biomarker in a cohort of tras-
tuzumab-treated breast cancer patients. This study illus-
trates the power of in vitro RNAi screens combined with
confirmation on patient samples to identify biomarkers
useful for predicting treatment response in the clinic.
Significant loss of PTEN expression is seen in some
20%–25% of HER2 positive breast cancers (Fujita et al.,
2006; Nagata et al., 2004; Saal et al., 2005; and our
data). Activating mutations in PIK3CA have also been
found in approximately 25% of primary breast cancers
and these occur almost exclusively in the PTEN positive
samples (Saal et al., 2005; and our data). Since both
(B) Progression-free survival for patients with a hotspot PIK3CA muta-
tion and for patients with no mutation in exon 9 or 20.
(C) Based on the PTEN scores and PIK3CA mutation data, patient
groups were divided in activated PI3K pathway (PTEN low or onco-
genic mutation in PIK3CA) and not-activated pathway (PTEN high +
wild-type PIK3CA).ncer Cell 12, 395–402, October 2007 ª2007 Elsevier Inc. 399
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Mutation on Time to Progression
n (Patients) n (Events) HRa 95% CI p
PTEN high 39 34 1.0
PTEN low 11 11 1.5 0.7–3.3 0.300
PIK3CA WT 40 34 1.0
PIK3CA mutant 14 14 1.6 0.8–3.3 0.210
Not-activated PI3K
pathway
29 24 1.0
Activated PI3K pathway 24 24 1.9 1.0–3.6 0.048
HR, hazard ratio; CI, confidence interval; WT, wild-type; Not-activated PI3K pathway, PTEN high + PIK3CA wild-type; Activated
PI3K pathway, PTEN low or PIK3CA mutant.
a Based on Cox regression with age as time scale, stratified for center, and adjusted for ER status.loss of PTEN and oncogenic mutation in PIK3CA lead to
activation of PI3K/AKT signaling (Isakoff et al., 2005) one
would expect that both genes can contribute to prediction
of response to trastuzumab. Indeed, our present data pro-
vide evidence that PIK3CA mutations contribute to in-
creased risk for progression (Figure 3B). In our analyses
PTEN status or PIK3CA mutation status alone had only
limited ability to predict prognosis after trastuzumab treat-
ment (Figure 3A). However, combined analysis of PTEN
status and PIK3CA status not only identified twice as
many patients at increased risk for disease progression,
but the combined analysis also reached statistical signifi-
cance as a biomarker for prognosis after trastuzumab
therapy (Figure 3C). Our data therefore indicate that as-
sessment of both PIK3CA mutation status and PTEN ex-
pression level likely reflecting pathway activation status
is required for optimal prediction of disease progression
after trastuzumab therapy in HER2 amplified breast
tumors. A recent study has identified the presence of
activating mutations in AKT1 in breast cancer (Carpten
et al., 2007). However, none of the 55 breast cancer tumor
samples studied here carried this mutation (unpublished
data), suggesting that AKT1 mutation was not a major
player in modulating trastuzumab responsiveness in this
patient cohort. It should be pointed out that most patients
analyzed here received a combination of trastuzumab and
chemotherapy, which may confound the results of this
study.
The present study highlights the central importance of
PI3K signaling in risk for progression after trastuzumab-
based therapy, which in turn suggests combination thera-
peutic strategies to treat trastuzumab unresponsive
breast cancer or to prevent emergence of resistance.
Our data merit the design of larger scale prospective clin-
ical trials to validate the use of PI3K pathway activation as
a biomarker for trastuzumab resistance in the clinic.
EXPERIMENTAL PROCEDURES
shRNA Barcode Screen
BT-474 cells were infectedwith retroviruses representing the complete
NKi RNAi library, selected with puromycin (2.0 mg/ml) and plated into400 Cancer Cell 12, 395–402, October 2007 ª2007 Elsevier Inctwo populations at low density. One population was left untreated,
while the other population was cultured in 10 mg/ml trastuzumab. After
4 weeks in culture the treated and untreated populations were col-
lected. Genomic DNA was isolated with the use of DNAzol (Life Tech-
nologies). The shRNA inserts were amplified from genomic DNA by
PCR. Purified PCR products were used for linear RNA amplification,
and purified RNA probes were labeled with cyanine-3 (Cy3) or cya-
nine-5 (Cy5) fluorescent groups (Kreatech). Labeled RNA probes
from untreated and trastuzumab-treated cells were combined and
hybridized to oligonucleotide arrays as described (Berns et al.,
2004). Quantification of the resulting fluorescent images was per-
formed with Imagene 5.6 (BioDiscovery), local background was
subtracted, and the data were normalized and 2log transformed. Addi-
tional information on barcode screens can be found at http://www.
screeninc.nki.nl/.
Phospho AKT Immunoblotting
Cell lysates were separated by 10%SDS-PAGE, transferred, and blots
were first probed with anti-pAKT (Ser473 #9271 Cell Signaling, Bev-
erly, MA) and subsequently reprobed with total AKT1/2 (H136 Santa
Cruz Biotechnology, Santa Cruz, CA). Immunoblotting was performed
according to the antibody manufacturer’s recommendations using
enhanced chemiluminescence.
Growth Curves
BT-474 cells were infected with the indicated retroviruses and poly-
clonal cell lines were seeded in 12-well plates (2.104 cells/well) and cul-
tured both in the absence and presence of 2 mg/ml trastuzumab. Cell
numbers were quantified at the indicated time points by fixing the cells
with 4% formaldehyde, staining the cells with crystal violet (0.1%
Sigma), extracting dye with 10% acetic acid, and determining the
optical density at 600 nm. Growth curves were performed multiple
times in triplicate.
Patients
For the NKI/AVL cohort, patients were eligible based on HER2 overex-
pression by immunohistochemistry (IHC 3+) and/or HER2 gene ampli-
fication by chromogenic in situ hybridization (CISH). Primary material
from 34 patients with HER2-overexpressing primary breast carcino-
mas who subsequently developed metastatic breast cancer and re-
ceived either trastuzumab monotherapy (n = 3), trastuzumab plus tax-
ane (n = 8), vinorelbine (n = 16), vinorelbine and lonafarnib (n = 5),
paclitaxel and carboplatin (n = 1), or adjuvant trastuzumab with pacli-
taxel and carboplatin for a locoregional recurrence (n = 1), was col-
lected from the NKI/AVL hospital and surrounding hospitals. This study
was approved by the Institutional Review Board of the Netherlands
Cancer Institute. Twenty-six of the tumors had high nuclear grade,
and ER status by IHC was positive in 14 and negative in 19 tumors.
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M.D. Anderson cohort, primary tumor material from 21 patients with
breast cancer that was confirmed as HER2 amplified (by FISH and/
or 3+ positivity on IHC) was obtained from the frozen breast tissue
tumor bank at M.D. Anderson Cancer Center under the auspices of
an IRB-approved protocol. Seventeen of the tumors had high nuclear
grade and ER status by IHC was positive in 12 and negative in 9
tumors. Patients were treated with trastuzumab monotherapy (n = 3)
or trastuzumab plus taxane (n = 8), vinorelbine (n = 6), or other chemo-
therapy (n = 4). Data on time to progression were available for all
patients.
Average age at diagnosis was 46.6 years and ranged from 25 to 74.1
(NKI: 47.8, 28.9–74.1, M.D. Anderson: 44.5, 25–65). Average time to
progression was 11.8 and ranged from 0.7 to 44.7 months (NKI:
11.3, 0.7–37.5, M.D. Anderson: 12.6, 0.8–44.7). During follow-up, 48
events occurred, and seven patients were censored (NKI: 29 and 5,
M.D. Anderson: 19 and 2). The prevalence of PIK3CA mutation was
25% (NKI: 21%, M.D. Anderson: 33%). Low PTEN expression was ob-
served in 22% of the patients (NKI: 24%, M.D. Anderson: 17%).
PIK3CA PCR, Sequencing, and Mutational Analysis
PCR reactions were performed on 10–100 ng of genomic DNA using
a standard protocol. PCR products were purified over a QIAquick
spin column (QIAGEN) and were sequenced using the BigDye Termi-
nator Cycle Sequencing Kit (Applied Biosystems) and an ABI 3730
automated capillary sequencer. For all PCR products with sequence
variants, both forward and reverse sequence reactions were repeated
for confirmation.
PIK3CA SNP Analysis
DNA around the known potential PIK3CA mutation hotspot sites 111,
542, 545, and 1047 was amplified and a primer extension reaction
was run to determine a potential SNP base using the Sequenom
(San Diego, CA) MALDI TOF MassArray system. The PCR reactions
were done and cleaned according to manufacturer’s instructions.
The primer extension reactions were done using Sequenom’s IPLEX
chemistry, and were then desalted using Sequenom’s Clean Resin
and spotted onto Spectrochip matrix chips using a Samsung Nanodis-
penser. The chips were then run on the SequenomMassArray. Seque-
nom Typer Software was used to interpret the mass spectra that were
generated and to report the SNPs based on expected masses. All
spectra generated were run in duplicate and were visually inspected.
Immunohistochemistry
Serial sections of 3 mm from the paraffin blocks were deparaffinized in
xylene, and hydrated in a graded series of alcohol. Staining was per-
formed using the Lab Vision Immunohistochemical Autostainer (Lab
Vision Corporation, Fremont, CA) with primary antibodies toward
PTEN (DAKO, 1:200), HER2 (clone 3B5, 1:3000) (van de Vijver et al.,
1988), and ER (estrogen receptor-a; 1D5+6F11, dilution 1:50, Neo-
markers, Lab Vision Corporation, Fremont, CA). Detection was per-
formed with antigen retrieval method (citrate pH 6.0).
Scoring
The PTEN expression level was scored semiquantitatively based on
staining intensity and distribution using the immunoreactive score
(IRS) as described elsewhere (Chui et al., 1996; Friedrichs et al.,
1993) (see Supplemental Experimental Procedures). Samples were
scored as ER positive by IHC, when at least more than 10% of the
tumor cells showed staining of the ER in the nuclei. A sample was con-
sidered to be HER2 positive when either a strong membrane staining
(3+) could be observed by IHC or CISH revealed amplification of
HER2 in samples with weak (1+ or 2+) membrane staining at IHC (Han-
nemann et al., 2006).
Statistical Analysis
We evaluated the association between time to progression and two
candidate risk factors, PIK3CA mutation and PTEN expression, usingCamultivariate Cox regression with age as the time scale. Follow-up
started at the age of diagnosis and ended at the age of progression,
the age at death, or the age at censoring, whichever came first. For cat-
egorization of the continuous PTEN expression values into low and
high, we chose a commonly used cut point for the measurements
(range 0–12, cut point < 3 versus > 3), which resulted in 22%of patients
being low. PTEN expression wasmissing for four subjects. All analyses
were stratified by center and adjusted for age by using this variable as
the time scale. Confounding was further evaluated for grade and ER
status. Kaplan-Meier plots were produced in order to graphically illus-
trate the event history by the two candidate risk factors. Log-rank tests
were performed to evaluate the homogeneity of group-specific survival
curves.
Supplemental Data
The Supplemental Data include Supplemental Experimental Proce-
dures, two supplemental figures, and one supplemental table and
can be found at http://www.cancercell.org/cgi/content/full/12/4/395/
DC1/.
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